In line with the strict correlation of K-Ras-nanoclustering with MAPK-signaling output [37], and with the effect of Hsp90 inhibitors on the abundance of Ras-effector kinases Raf and Akt [11], we found decreased pERK and Akt levels in KRAS-G13D mutant MDA-MB-231 triple-negative breast cancer cells upon treatment with conglobatin A (Figure 2B). This evidence concerns the gene KRAS and triple-negative breast carcinoma.